Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial

American Journal of Kidney Diseases

Volumn 52, Issue 3, 2008, Pages 486-493

  Tylicki, Leszek ^a   Rutkowski, Przemysław ^a   Renke, Marcin ^a   Larczyński, Wojciech ^a   Aleksandrowicz, Ewa ^a   Lysiak Szydlowska, Wiesława ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

ACE inhibitor; aldosterone receptor blocker; angiotensin receptor blocker; Proteinuria; renin angiotensin aldosterone system; spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDROCHLOROTHIAZIDE; N ACETYL BETA GLUCOSAMINIDASE; POTASSIUM; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOL; SPIRONOLACTONE; TELMISARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MALE; MORNING DOSAGE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CHRONIC DISEASE; CILAZAPRIL; COLLAGEN TYPE III; CROSS-OVER STUDIES; DISEASE PROGRESSION; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; KIDNEY DISEASES; MALE; POTASSIUM; PROTEINURIA; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 49749125234     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.02.297     Document Type: Article

References (30)

1. Tylicki L., Larczynski W., and Rutkowski B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: From evidence-based approach to perspectives. Kidney Blood Press Res 28 (2005) 230-242
2. Remuzzi G., Perico N., Macia M., and Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99 (2005) S57-S65
3. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361 (2003) 117-124
4. Ruggenenti P., and Remuzzi A. Is therapy with combined ACE inhibitor and angiotensin receptor antagonist the new gold standard of treatment for nondiabetc, chronic proteinuric nephropathies?. NephSAP 2 (2003) 235-237
5. Rutkowski P., Tylicki L., Renke M., et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 43 (2004) 260-268
6. Tylicki L., Biedunkiewicz B., Chamienia A., et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 7 (2007) 243-248
7. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int 66 (2004) 1-9
8. Iglarz M., Touyz R.M., Viel E.C., Amiri F., and Schiffrin E.L. Involvement of oxidative stress in the profibrotic action of aldosterone: Interaction with the renin-angiotension system. Am J Hypertens 17 (2004) 597-603
9. Arima S., Kohagura K., Xu H.L., et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14 (2003) 2255-2263
10. Lakkis J., Lu W., and Weir M. RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5 (2003) 408-417
11. Maroni B.J., Steinman T.I., and Mitch W.E. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27 (1985) 58-65
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
13. Maruhn D. Rapid calorimetric assay of β-galactosidase and N-acetyl-β-d-glucosaminidase in human urine. Clin Chim Acta 73 (1976) 453-461
14. Bianchi S., Bigazii R., and Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006) 2116-2123
15. Chrysostomou A., and Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 (2001) 925-926
16. Senn S. Cross-over Trials in Clinical Research (2002), Wiley, Chichester, NY
17. Grubbs F.E. Procedures for detecting outlying observations. Technometrics 11 (1969) 1-21
18. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70 (2006) 536-542
19. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., and Parving H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28 (2005) 2106-2112
20. Nitta K., Uchida K., and Nihei H. Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am J Med 117 (2004) 444-445
21. Aranda P., Segura J., Ruilope L.M., et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 46 (2005) 1074-1079
22. Minutolo R., Gabbai F.B., Borrelli S., et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: An 8-week uncontrolled trial. Am J Kidney Dis 50 (2007) 908-917
23. Butter H., Hemmelder M., Navis G., De Jong P., and De Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13 (1998) 1682-1685
24. Kramer A.B., van der Meulen E.F., Hamming I., van Goor H., and Navis G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 71 (2007) 417-424
25. Abbate M., Zoja C., Rottoli D., et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein-and complement-dependent interstitial inflamation in experimental renal disease. J Am Soc Nephrol 10 (1999) 804-813
26. Teppo A.M., Tornroth T., Honkanen E., and Gronhagen-Riska C. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 75 (2003) 2113-2119
27. Bazzi C., Petrini C., Rizza V., et al. Urinary N-acetylglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 17 (2002) 1890-1896
28. Holdt-Lehmann B., Lehmann A., Korten G., et al. Diagnostic value of urinary alanine aminopeptidase and N-acetyl-β-d-glucosaminidase in comparison to alfa-1 microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 297 (2000) 93-102
29. Sawathiparnich P., Murphey L.J., Kumar S., Vaughan D.E., and Brown N.J. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88 (2003) 3867-3873
30. Wrenger E., Muller R., Moesenthin M., et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: Analysis of 44 cases. BMJ 327 (2003) 147-149